56
Participants
Start Date
October 31, 2015
Primary Completion Date
March 28, 2018
Study Completion Date
March 28, 2018
Parts A/B: Adrabetadex
900 - 1800 milligram (mg) of adrabetadex administered every 2 weeks via lumbar intrathecal infusion
Parts A/B: Sham Control
No experimental drug is administered to participants - intrathecal administrations are simulated by skin prick
The Prince of Wales Hospital, Sydney
Royal Melbourne Hospital, Parkville
Monash Medical Centre, Clayton
Waikato Hospital, Hamilton West
Royal Perth Hospital, Perth
Montefiore Medical Center, The Bronx
Lehigh Valley Health Network, Allentown
The Children's Hospital of Philadelphia, Philadelphia
University of North Carolina, Chapel Hill
Shands Children's Hospital, Gainesville
University of Alabama at Birmingham, Birmingham
Katholisches Klinikim Bochum gGmbH, Bochum
Universitaetsklinikum Muenster, Münster
Universitaetsklinikum Mainz, Mainz
Rush University Medical Center, Chicago
Dell Children's Medical Center of Central Texas, Austin
University of Colorado Denver, Aurora
Children's Hospital of Orange County, Orange
Multicare Institute for Research and Innovation, Tacoma
National University Hospital (Singapore) Pte, Ltd, Singapore
University of California San Francisco, San Francisco
Eunice Kennedy Shriver National Institute of Child Health and Human Development, Bethesda
Boston Children's Hospital, Boston
CHU Paris Est - Hospital d'Enfants Armand-Trousseau, Paris
Hospital Universitario del Valle Hebron, Barcelona
Hacettepe University Medical Faculty, Altındağ
Gazi University Medical Faculty, Çankaya
Birmingham Women's and Children's NHS Trust, Birmingham
Great Ormond Street Hospital, London
Mandos LLC
INDUSTRY